StockTipsArenaBeta

BUY Sun Pharmaceutical Industries Ltd. — Somil Mehta, Sharekhan

BUYSun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries share price target & all analyst calls

bySomil Mehta, SharekhanHorizon: NA (inferred Swing (≤2wk))21 Sept 2026via CNBC Awaaz.

Entry₹1,884Inferred
Target₹2,000
Total upside +6.16% (call closed)
Stop loss₹1,830-2.87% risk
Exit₹1,83030 Sept 2026, 10:00 am
Stop-loss hit-2.87%
Follow Somil Mehta for new calls(26% target hit, 293 closed calls)Get alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 1 active Swing call on SUNPHARMASee 282 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 30 Sept 2026
2 supporting1 neutral1 opposing
Supports the BUY call (2)

Sun Pharmaceutical has entered into a licensing agreement for lerodalcibep, a novel drug candidate, expanding its specialty portfolio.

BSE · Company Update·28 Sept · 2d ago

(opens in new tab)

5 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·23 Sept · 1w ago

Neutral / worth noting (1)

Sun Pharmaceutical Industries Ltd has been assigned international issuer credit ratings by Moody's Ratings (Baa1, Stable Outlook) and S&P Global Ratings (BBB+, Stable Outlook). These ratings are inves

BSE · Company Update·8 Sept · 3w ago

(opens in new tab)
Weighs against the BUY call (1)

Sun Pharma subsidiaries settle US generic drug pricing antitrust case for confidential amount

NewsCnbc-Tv18·11 Sept · 3w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Sun Pharmaceutical Industries

All analyst calls on Sun Pharmaceutical Industries

More from Somil Mehta, Sharekhan

Every call and its outcome